Safety evaluation and pharmacodynamics of minocycline hydrochloride eye drops
Xiaoli Li1, Wenhua Zhang1, Zhiqiang Ye2
1Henan Eye Institute, Henan Eye Hospital, Henan Provincial People's Hospital, Henan University People's Hospital, Zhengzhou, China.
Purpose:
This study evaluated the safe dosage of minocycline hydrochloride (Mino) eye drops and investigated the potential for the prevention or reduction of retinal damage in a diabetic rat model.
Methods:
Various concentrations of Mino were applied to human corneal epithelial cells (HCECs) to determine the half maximal inhibitory concentration (IC50). The safety of Mino eye drops was evaluated on Sprague-Dawley (SD) rat eyes by slit-lamp examination, electroretinography (ERG), histology, and TUNEL assay. Eye drops (1 mg/ml) were applied to the streptozotocin-induced diabetic SD rats. Clinical observations, ERG analyses, and optical coherence tomography analyses were performed monthly for five months. Eyes were then analyzed via histology, blood-retinal barrier function assay, and retinal vascular staining.
Results:
Cytotoxicity analysis using HCECs revealed that the IC50 was 250 µg/ml. Safety analyses in healthy SD rats showed that Mino eye drops did not demonstrate any ocular toxicity. Pharmacodynamics analysis showed that retinal thickness at three months was greater in the Mino group than in the non treated (NT) group. The peak times and amplitudes of each program were better in the Mino group than in the NT group at each time point by ERG analyses. Histology examinations showed a thinner ganglion cell layer, fewer ganglion cells, and more dilated blood vessels in the NT group than in the Mino group.
Conclusion:
Mino eye drops at 1 mg/ml were safe when used in SD rats. Mino eye drops can protect the retina from the development or progression of diabetic retinopathy.
Insights
Minocycline hydrochloride eye drops are safe and may prevent or reduce retinal damage in diabetic rats, offering a potential treatment for diabetic retinopathy.
Area of Science:
- Ophthalmology
- Pharmacology
- Diabetic Retinopathy Research
Background:
- Diabetic retinopathy is a leading cause of vision loss.
- Current treatments have limitations, necessitating novel therapeutic approaches.
Purpose of the Study:
- To evaluate the safety and efficacy of minocycline hydrochloride (Mino) eye drops.
- To investigate Mino's potential in preventing or reducing retinal damage in a diabetic rat model.
Main Methods:
- Determined Mino's IC50 in human corneal epithelial cells (HCECs).
- Assessed Mino eye drop safety in Sprague-Dawley (SD) rats via clinical, electroretinography (ERG), and histological analyses.
- Administered 1 mg/ml Mino eye drops to diabetic SD rats for five months, monitoring retinal health through various assays.
Main Results:
- Mino eye drops demonstrated no ocular toxicity in healthy rats.
- Diabetic rats treated with Mino showed increased retinal thickness and improved ERG parameters compared to controls.
- Histological analysis revealed preservation of the ganglion cell layer and reduced vascular abnormalities in the Mino-treated group.
Conclusions:
- Minocycline hydrochloride eye drops at 1 mg/ml are safe for ocular use in rats.
- Mino eye drops show potential for protecting the retina against the development or progression of diabetic retinopathy.
